專家問答：支持線上顧問委員會並提高 KOL 參與度

虛擬顧問委員會正成為尋求有效吸引關鍵意見領袖 (KOL) 的製藥公司的重要工具。透過利用數位平台，虛擬諮詢委員會可以實現即時討論、全球參與和簡化決策。

在本報告中，我們採訪了 Republic M! 的虛擬大客戶經理 John Halladay。小組討論了虛擬董事會不斷擴大的角色、其缺點和好處，以及公司如何優化其影響力。

報告內容

• 與傳統的面對面會議相比，虛擬顧問委員會如何改變製藥公司與 KOL 互動的方式
• 虛擬顧問委員會在增強 KOL 參與度和參與度方面的潛在優勢
• 虛擬顧問委員會可以使用哪些策略來提供符合 KOL 期望和興趣的價值？
• 我們如何能最大限度地參與虛擬顧問委員會？
• 可以採取哪些方法來激發為期數週的虛擬顧問委員會會議的參與度？
• 您可以提前做些什麼來增加虛擬顧問委員會會議期間的參與度？
• 虛擬顧問委員會會議結束後，哪些後續活動和參與策略可以幫助 KOL 保持參與度和積極性？
• 虛擬平台需要具備哪些重要功能才能滿足顧問委員會會議的特定參與要求？
• 虛擬顧問委員會如何提供自發性、非腳本式對話的機會，同時仍保持結構化的議程？
• 如果 KOL 要求就特定主題進行更深入的討論，公司如何準備在虛擬顧問委員會會議期間提供額外的材料或資訊？
• 可以使用哪些指標和回饋機制來評估 KOL 的參與度，以及公司可以如何根據這些回饋採取行動來增強未來的參與度？
• KOL 參與虛擬顧問委員會面臨的 3 大課題
• 您希望看到虛擬顧問委員會做出哪些改變，以進一步增強 KOL 的參與度？
• 在虛擬顧問委員會時代增強 KOL 參與度

Virtual advisory boards are becoming an essential tool for pharmaceutical companies seeking to engage key opinion leaders (KOLs) efficiently and effectively. By leveraging digital platforms, these virtual boards allow for real-time discussions, global participation and streamlined decision making - without the logistical challenges of in-person meetings.

FirstWord spoke with John Halladay, virtual key account manager at Republic M! Group, about the growing role of virtual advisory boards, their drawbacks and advantages, and how companies can optimise their impact.

Key Questions Answered:

• How have virtual advisory boards changed the way pharmaceutical companies engage with KOLs compared with traditional, in-person meetings?
• What are some potential advantages of virtual advisory boards for enhancing KOL engagement and participation?
• What strategies have been effective during virtual advisory boards for providing value that aligns with KOLs' expectations and interests?
• What methods can be used to maximise engagement during virtual advisory boards?
• What approaches have been beneficial for eliciting engagement from virtual advisory boards that span several weeks?
• What can be done prior to the virtual advisory board to increase engagement during the event?
• What follow-up activities or engagement strategies can help maintain KOL involvement and collaboration after the virtual advisory board concludes?
• What features are important for a virtual platform to meet the specific engagement requirements of an advisory board meeting?
• How can virtual advisory boards incorporate opportunities for spontaneous, off-script conversations while still maintaining a structured agenda?
• How might companies prepare to provide additional materials or information during a virtual advisory board if KOLs request more detailed discussion on specific topics?
• What metrics or feedback mechanisms can be used to assess KOL engagement, and how can companies act on this feedback to enhance future engagement?
• What are the three biggest challenges to KOL engagement in virtual advisory boards?
• What changes do you anticipate in virtual advisory boards to further enhance KOL engagement?
• Do you have any concluding thoughts on the topic of enhancing KOL engagement in the era of virtual advisory boards?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.